FindTrial
Sign In

The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake

The Effect of Acute HMG-CoA-Reductase Inhibition (Atorvastatin) on Renal Sodium Excretion, Renal Hemodynamics, Tubular Function and Vasoactive Hormones in Healthy Subjects During Normal and High Sodium Intake

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00678184
Enrollment
23
Registered
2008-05-15
Start date
2007-01-31
Completion date
2007-10-31
Last updated
2008-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Keywords

Atorvastatin, healthy, sodium excretion, hemodynamics, tubular function

Brief summary

We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium handling, renal hemodynamics, tubular function and vasoactive hormones in healthy humans during normal and high sodium intake.

Detailed description

We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium handling, renal hemodynamics, tubular function and vasoactive hormones in healthy humans during normal and high sodium intake. We wanted to analyze if changes in renal hemodynamics, tubular function, hormones, blood pressure and HR under acute treatment with atorvastatin depends on sodium intake.

Interventions

DRUGAtorvastatin

80 mg atorvastatin on two following days each

Sponsors

Regional Hospital Holstebro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 20-50 yr 2. BMI\<30 3. Females had to use oral contraceptive treatment or IUD.

Exclusion criteria

1. Clinical signs or history of disease of the heart, lungs, kidneys, liver, brain or endocrine organs 2. Abnormal laboratory blood tests (hemoglobin, sodium, potassium, albumin, creatinine, blood glucose, bilirubin, alanin amino transferase, alkalic phosphatase) 3. Albuminuria or glucosuria 4. cancer 5. arterial hypertension 6. alcohol abuse 7. medical treatment, except contraceptives 8. pregnancy or breast feeding 9. blood donation one month before the study.

Design outcomes

Primary

MeasureTime frame
Glomerular filtration rate, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, free water clearance6 months

Secondary

MeasureTime frame
AVP, Ang-II, Aldosterone, ANP, BNP, PRC, BP and HR.6 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026